LU ZHANG^*, JINGUO CHU^*, YUSHAN YU

Oncology Research, Vol.32, No.4, pp. 703-716, 2024, DOI:10.32604/or.2023.030988

Abstract Background: Limited research has been conducted on the influence of autophagy-associated long non-coding RNAs (ARLncRNAs) on the prognosis of hepatocellular carcinoma (HCC). Methods: We analyzed 371 HCC samples from TCGA, identifying expression networks of ARLncRNAs using autophagy-related genes. Screening for prognostically relevant ARLncRNAs involved univariate Cox regression, Lasso regression, and multivariate Cox regression. A Nomogram was further employed to assess the reliability of Riskscore, calculated from the signatures of screened ARLncRNAs, in predicting outcomes. Additionally, we compared drug sensitivities in patient groups with differing risk levels and investigated potential biological pathways through enrichment analysis, using consensus clustering to identify subgroups… More >

HAN WANG, YINGYING ZHOU, SIYANG ZHANG, YA QI, MIN WANG^*

Oncology Research, Vol.29, No.4, pp. 275-289, 2021, DOI:10.32604/or.2022.03561

Abstract Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the transcripts of small… More >

Xingjun Meng^1,#, Zhihui Cao^2,#, Renfeng Liu^3,#, Kai Zheng⁴, Shuai Ding⁵, Yuefan Gu⁴, Yonghua Chen⁶, Jun Lv⁷, Ping Li⁸, Li Zhou⁹, Wenbo Wang¹⁰, Shiliang Ji¹¹, Hui He^12,*, Hui Yang^9,*

Oncologie, Vol.24, No.2, pp. 283-294, 2022, DOI:10.32604/oncologie.2022.021259

Abstract It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor progression, we chose paclitaxel and… More >

DULCE MA. BARRADAS-DERMITZ^1,*, PATRICIA M. HAYWARD-JONES², MARTÍN MATA-ROSAS³, BEATRIZ PALMEROSSÁNCHEZ², OSCAR B. J. PLATAS-BARRADAS⁴, RODOLFO F. VELÁSQUEZ-TOLEDO²

BIOCELL, Vol.34, No.1, pp. 1-6, 2010, DOI:10.32604/biocell.2010.34.001

Abstract Of the initial six cell lines originating from explants of Taxus globosa, or Mexican yew (stem internode, leaves and meristematic tissue), three were selected for their microbial and oxidation resistance, two from leaves and the other from stem internode. A study of their behavior, both in terms of cell growth, and of baccatin III and paclitaxel production, was developed in suspension cultures with an initially standardized biomass (fresh weight 0.23 g/L) using modified Gamborg’s B5 medium, and an elicitor (methyl jasmonate), on either the first or seventh day of culture, at several levels (0, 0.1, 1, 10, 100 μM). In… More >